866-997-4948(US-Canada Toll Free)

Viralytics Ltd. Product Pipeline Review 2012

Published By :

Global Markets Direct

Published Date : Dec 2012

Category :

Pharmaceutical

No. of Pages : 46 Pages


Global Market Directs pharmaceuticals report, Viralytics Ltd. - Product Pipeline Review - 2012 provides data on the Viralytics Ltd.s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. 

This report is built using data and information sourced from Global Markets Directs proprietary databases, Viralytics Ltd.s corporate website, SEC filings, investor presentations and featured press releases, both from Viralytics Ltd. and industry-specific third party sources, put together by Global Markets Directs team. 

Scope

  • Viralytics Ltd. - Brief Viralytics Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
  • Review of current pipeline of Viralytics Ltd. human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
  • Product profiles for late stage and clinical stage products of Viralytics Ltd. with complete description of the products developmental history, mechanism of action, therapeutic class, target and major milestones. 
  • Recent updates of the Viralytics Ltd.s pipeline in the last quarter. 
  • Key discontinued and dormant projects. 
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Viralytics Ltd.s strategic position with total access to detailed information on its product pipeline. 
  • Assess the growth potential of Viralytics Ltd. in its therapy areas of focus. 
  • Identify new drug targets and therapeutic classes in the Viralytics Ltd.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. 
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. 
  • Exploit collaboration and partnership opportunities with Viralytics Ltd.. 
  • Avoid Intellectual Property Rights related issues. 
  • Explore the dormant and discontinued projects of Viralytics Ltd. and identify potential opportunities in those areas.
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Viralytics Ltd. Snapshot 5
Viralytics Ltd. Overview 5
Key Information 5
Key Facts 5
Viralytics Ltd. Research and Development Overview 6
Key Therapeutic Areas 6
Viralytics Ltd. Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products Monotherapy 10
Pipeline Products Combination Treatment Modalities 11
Viralytics Ltd. Pipeline Products Glance 12
Viralytics Ltd. Clinical Stage Pipeline Products 12
Phase II Products/Combination Treatment Modalities 12
Phase I Products/Combination Treatment Modalities 13
Viralytics Ltd. Early Stage Pipeline Products 14
Pre-Clinical Products/Combination Treatment Modalities 14
Discovery Products/Combination Treatment Modalities 15
Viralytics Ltd. Drug Profiles 16
CAVATAK + [doxorubicin] 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Coxsackievirus A13 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Coxsackievirus A15 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Coxsackievirus A18 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CVA-21 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
CVA21-DAFv 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Evatak 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Viralytics Ltd. Pipeline Products by Route of Administration 27
Viralytics Ltd. Pipeline Products By Mechanism of Action 28
Viralytics Ltd. Recent Pipeline Updates 30
Viralytics Ltd. Locations And Subsidiaries 32
Head Office 32
Viralytics Ltd., Recent Developments 33
Viralytics Ltd.- Press Release 33
Nov 12, 2012: Viralytics Presents Phase I Data On Cavatak At EORTC-NCI-AACR Symposium 33
Feb 15, 2012: Viralytics Receives US Patent Covering Coxsackie A Virus 33
Jan 19, 2012: Viralytics Provides Update On Three Clinical Trials Of CAVATAK 34
Dec 18, 2009: Viralytics Receives Approval To Increase CAVATAK Dosage In Head And Neck Cancer Trial 34
Financial Deals Landscape 36
Viralytics Ltd., Deals Summary 36
Viralytics Ltd., Pharmaceuticals & Healthcare, Deal Details 37
Equity Offering 37
Viralytics Completes Private Placement Of $1.38 Million 37
Viralytics Completes Public Offering Of $0.57 Million 39
Viralytics Completes Private Placement Of $1.25 Million 41
Viralytics Completes Public Offering Of $1.65 Million 42
Psiron Completes Private Placement Of $1.33 Million 43
Debt Offering 44
Viralytics Completes Private Placement Of Convertible Note For $6 Million 44

Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Table


Viralytics Ltd., Key Information 5
Viralytics Ltd., Key Facts 5
Viralytics Ltd. Pipeline by Indication, 2012 8
Viralytics Ltd. Pipeline by Stage of Development, 2012 9
Viralytics Ltd. Monotherapy Products in Pipeline, 2012 10
Viralytics Ltd. Combination Treatment Modalities in Pipeline, 2012 11
Viralytics Ltd. Phase II, 2012 12
Viralytics Ltd. Phase I, 2012 13
Viralytics Ltd. Pre-Clinical, 2012 14
Viralytics Ltd. Discovery, 2012 15
Viralytics Ltd. Pipeline By Route of Administration, 2012 27
Viralytics Ltd. Pipeline Products By Mechanism of Action, 2012 29
Viralytics Ltd. Recent Pipeline Updates, 2012 30
Viralytics Ltd., Deals Summary 36
Viralytics Completes Private Placement Of $1.38 Million 37
Viralytics Completes Public Offering Of $0.57 Million 39
Viralytics Completes Private Placement Of $1.25 Million 41
Viralytics Completes Public Offering Of $1.65 Million 42
Psiron Completes Private Placement Of $1.33 Million 43
Viralytics Completes Private Placement Of Convertible Note For $6 Million 44

List of Chart


Viralytics Ltd. Pipeline by Indication, 2012 7
Viralytics Ltd. Pipeline by Stage of Development, 2012 9
Viralytics Ltd. Monotherapy Products in Pipeline, 2012 10
Viralytics Ltd. Combination Treatment Modalities in Pipeline, 2012 11
Viralytics Ltd. Pipeline By Route of Administration, 2012 27
Viralytics Ltd. - Pipeline Products By Mechanism of Action, 2012 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *